News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Vibeke Strand, MD

Articles by Vibeke Strand, MD

Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence

ByVibeke Strand, MD,Colby Evans, MD,Allan Gibofsky, MD, JD

November 1st 2022

Biosimilar medicines: what are they and how are they used?

ByVibeke Strand, MD,Colby Evans, MD,Allan Gibofsky, MD, JD

November 1st 2022

Plain Language Summary

Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

ByAllan Gibofsky, MD, JD,Colby Evans, MD,Vibeke Strand, MD

November 1st 2022

What do patients and health care providers still need to know about biosimilar medicines?

ByAllan Gibofsky, MD, JD,Colby Evans, MD,Vibeke Strand, MD

November 1st 2022

Plain Language Summary

eAppendix: Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

ByAllan Gibofsky, MD, JD,Colby Evans, MD,Vibeke Strand, MD

November 1st 2022

Biosimilars for Immune-Mediated Inflammatory Diseases – A Managed Care Perspective

ByColby Evans, MD,Allan Gibofsky, MD, JD,Vibeke Strand, MD

November 1st 2022

What are the current challenges to wider biosimilar use in the United States?

ByColby Evans, MD,Allan Gibofsky, MD, JD,Vibeke Strand, MD

November 1st 2022

Plain Language Summary

Improved Health-related Quality of Life With Effective Disease-modifying Antirheumatic Drugs: Evidence From Randomized Controlled Trials

ByVibeke Strand, MD,Jasvinder A. Singh, MD, MPH

April 15th 2008

Latest Updated Articles

Biosimilars for Immune-Mediated Inflammatory Diseases – A Managed Care Perspective
Published: November 1st 2022 | Updated:
Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence
Published: November 1st 2022 | Updated:
Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys
Published: November 1st 2022 | Updated:
Improved Health-related Quality of Life With Effective Disease-modifying Antirheumatic Drugs: Evidence From Randomized Controlled Trials
Published: April 15th 2008 | Updated:

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

5 Things to Know About the Oral GLP-1 Era

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention

Exploring Identity, Appearance Experiences Among Patients With Alopecia

Real-World Evidence Backs Acalabrutinib in CLL Care

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text